These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 9135525)
1. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525 [TBL] [Abstract][Full Text] [Related]
2. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring]. Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303 [TBL] [Abstract][Full Text] [Related]
3. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Hammel P; Leroy-Viard K; Chaumette MT; Villaudy J; Falzone MC; Rouillard D; Hamelin R; Boissier B; Remvikos Y Int J Cancer; 1999 May; 81(5):712-8. PubMed ID: 10328221 [TBL] [Abstract][Full Text] [Related]
4. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters. Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964 [TBL] [Abstract][Full Text] [Related]
5. p53 and follow-up of colorectal adenocarcinomas. Polge A; Bourgaux JF; Bancel E; Pignodel C; Boyer JC; Poirey S; de Bornier BM; Balmes JL; Bali JP Dig Dis Sci; 1998 Jul; 43(7):1434-42. PubMed ID: 9690377 [TBL] [Abstract][Full Text] [Related]
6. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies. Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530 [TBL] [Abstract][Full Text] [Related]
7. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775 [TBL] [Abstract][Full Text] [Related]
8. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664 [TBL] [Abstract][Full Text] [Related]
9. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA. Ushigome M; Shimada H; Miura Y; Yoshida K; Kaneko T; Koda T; Nagashima Y; Suzuki T; Kagami S; Funahashi K Int J Clin Oncol; 2020 Apr; 25(4):622-632. PubMed ID: 31820210 [TBL] [Abstract][Full Text] [Related]
10. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer. Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Suwa H; Ohshio G; Okada N; Wang Z; Fukumoto M; Imamura T; Imamura M Gut; 1997 May; 40(5):647-53. PubMed ID: 9203945 [TBL] [Abstract][Full Text] [Related]
12. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624 [TBL] [Abstract][Full Text] [Related]
14. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Houbiers JG; van der Burg SH; van de Watering LM; Tollenaar RA; Brand A; van de Velde CJ; Melief CJ Br J Cancer; 1995 Sep; 72(3):637-41. PubMed ID: 7669574 [TBL] [Abstract][Full Text] [Related]
15. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Chang SC; Lin JK; Lin TC; Liang WY Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226 [TBL] [Abstract][Full Text] [Related]
16. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection. Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942 [TBL] [Abstract][Full Text] [Related]
17. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Takeda A; Shimada H; Nakajima K; Yoshimura S; Suzuki T; Asano T; Ochiai T; Isono K Int J Clin Oncol; 2001 Feb; 6(1):45-9. PubMed ID: 11706527 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. Takeda A; Nakajima K; Shimada H; Imaseki H; Takayama W; Hayashi H; Suzuki T; Ochiai T; Isono K J Surg Oncol; 1999 Jun; 71(2):112-6. PubMed ID: 10389868 [TBL] [Abstract][Full Text] [Related]
19. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125 [TBL] [Abstract][Full Text] [Related]
20. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan. Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]